Through recent research, there has been great advancement in the treatment of NSCLC patients with epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma receptor tyrosine kinase (ALK) rearrangement (3–6). Here, ALK is linked to non-small cell lung carcinoma.